65 completed, 15 unknown, 10 recruiting, 10 terminated. 111 Phase 2, 36 Phase 1, 18 Phase 3.
Follow Spinal Cord Injury: new trials by email Literature Review of Spinal Cord Injury trials Research Report on Spinal Cord Injury
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells, Placebo - Spinal Cord Injury, Safety | Phase 2 | Not yet recruiting | XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | 60 | 2028-05-25 | 2025-11-25 |
| Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial testosterone cypionate, finasteride, placebo injection - Spinal Cord Injury, Spinal Cord Injuries | Phase 2 / Phase 3 | Not yet recruiting | VA Office of Research and Development | 300 | 2027-10-01 | 2026-08-04 |
| Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI) Galantamine Hydrobromide Extended Release - Spinal Cord Injury, Traumatic Spinal Cord Injury | Phase 2 / Phase 3 | Recruiting | Northwell Health | 60 | 2026-10-15 | 2026-11-04 |
| Extracorporeal Shockwave Therapy as an Additional Treatment for Spasticity Secondary to Spinal Cord Injury Focused extracorporeal shockwave therapy, Botulinum toxin, Sham - Spinal Cord Injury, Spasticity | Phase 2 | Recruiting | Kessler Foundation | 30 | 2026-09-21 | 2026-11-04 |
| Psilocybin to Treat Depression in Spinal Cord Injury Psilocybin (Usona Institute) - Spinal Cord Injury, Depression - Major Depressive Disorder | Phase 1 / Phase 2 | Recruiting | James J. Peters Veterans Affairs Medical Center | 30 | 2026-08-06 | 2026-08-10 |
| Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy Urodynamics, EG110A, Patient-reported Outcome - Urinary Bladder, Overactive, Spinal Cord Injury | Phase 1 / Phase 2 | Not yet recruiting | Cyllene Therapeutics | 16 | 2026-04-01 | 2025-11-12 |
| CE-STAND: Cervical Epidural STimulation After Neurologic Damage Epidural Spinal Cord Stimulation System - Spinal Cord Injury | Phase 1 / Phase 2 | Recruiting | University of Minnesota | 36 | 2026-03-15 | 2026-03-27 |
| CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury CBD - Supra-sacral Spinal Cord Injury, Spinal Cord Injury | Phase 2 | Recruiting | University of Wisconsin, Madison | 20 | 2026-02-13 | 2026-09-16 |
| Improving Walking After Spinal Cord Injury Paired Associative Stimulation, Locomotor Training, Sham stimulation - Spinal Cord Injury | Phase 1 / Phase 2 | Not yet recruiting | Shirley Ryan AbilityLab | 20 | 2025-11-15 | 2025-11-03 |
| Improving 24-hour Blood Pressure Stability in Spinal Cord Injury With Low Oxygen Therapy Low oxygen therapy (LOT) - Spinal Cord Injury | Phase 1 / Phase 2 | Recruiting | Glen Foster | 10 | 2025-10-23 | 2025-11-18 |
| Guttmann NeuroRecovery - Viability, Safety, and Efficacy of Intrathecal Wharton's Jelly Mesenchymal Stem Cells and Transcutaneous Spinal Cord Stimulation in Chronic Spinal Cord Injury Rehabilitation Allogeneic Wharton's jelly mesenchymal stem cells (WJ-MSCs) - Spinal Cord Injuries (SCI), Spinal Cord Injury | Phase 1 / Phase 2 | Not yet recruiting | Institut Guttmann | 10 | 2025-09-01 | 2025-05-25 |
| Paired Stimulation Plasticity for Motor Recovery in Humans With and Without Spinal Cord Injury CST PAS, RST PAS, sham PAS - Healthy Control, Spinal Cord Injury | Phase 2 | Recruiting | Shirley Ryan AbilityLab | 300 | 2025-08-28 | 2026-10-14 |
| First-in-Human Clinical Trial of STUP-001, an In Vivo Direct Cell Conversion Gene Therapy for AIS-A/B Chronic Spinal Cord Injury STUP-001 - Spinal Cord Injury, Chronic Spinal Cord Injury | Phase 1 / Phase 2 | Recruiting | Yonsei University | 9 | 2025-07-30 | 2025-07-16 |
| Treating Central Neuropathic Pain With Low Dose Naltrexone for People With Spinal Cord Injury 4.5mg daily dose of naltrexone - Central Neuropathic Pain, Spinal Cord Injury | Phase 2 | Completed | Medical College of Wisconsin | 11 | 2025-02-01 | 2026-11-02 |
| Synergistic Effect of Non-invasive Brain and Spinal Cord Stimulation tDCS, tSCS, Sham - Stroke, Spinal Cord Injury | Phase 2 | Recruiting | Centre National de la Recherche Scientifique, France | 45 | 2024-12-11 | 2026-01-12 |
| Effects of Electrical Stimulation and Vitamin D Supplementation on Bone Health Following Spinal Cord Injury. NMES, Vitamin D, Passive movement - Spinal Cord Injury | Phase 2 / Phase 3 | Completed | VA Office of Research and Development | 6 | 2021-10-01 | 2026-01-23 |
| Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury MT-3921, Placebo - Spinal Cord Injury | Phase 2 | Completed | Tanabe Pharma America, Inc. | 72 | 2021-08-27 | 2025-12-16 |
| Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury Testosterone Enanthate, Locomotor Training - Spinal Cord Injury, Spinal Cord Injuries | Phase 2 | Recruiting | North Florida Foundation for Research and Education | 21 | 2021-01-31 | 2025-05-06 |
| Autologous Bone Marrow-derived Mononuclear Cells for Acute Spinal Cord Injury Autologous bone marrow-derived mononuclear cells, Placebo - Spinal Cord Injury | Phase 2 | Unknown | Shanghai Changzheng Hospital | 45 | 2020-10-01 | 2021-07-07 |
| Neuromodulation Techniques After SCI EAW+SCES (exoskelton and spinal cord epidural stimulation), EAW+TS (exoskelton and transspinal stimulation) - Spinal Cord Injury | Phase 2 | Completed | VA Office of Research and Development | 4 | 2020-06-01 | 2026-04-28 |
Showing 20 of 111. Sign in to see all of them.
Spinal Cord Injuries (111) · Quadriplegia (12) · Paraplegia (10) · Wounds and Injuries (9) · Spinal Cord Diseases (7) · Central Nervous System Diseases (6) · Nervous System Diseases (6) · Chronic Pain (5) · Neuralgia (5) · Neurologic Manifestations (5) · Bone Diseases (4) · Bone Diseases, Metabolic (4) · Hypogonadism (4) · Hypotension, Orthostatic (4) · Musculoskeletal Diseases (4)
Trauma, Nervous System (108) · Central Nervous System Diseases (105) · Nervous System Diseases (105) · Spinal Cord Diseases (104) · Wounds and Injuries (102) · Pathological Conditions, Signs and Symptoms (36) · Signs and Symptoms (35) · Neurologic Manifestations (25) · Paralysis (11) · Pain (9) · Nutritional and Metabolic Diseases (8) · Autonomic Nervous System Diseases (7) · Metabolic Diseases (7) · Cardiovascular Diseases (6) · Male Urogenital Diseases (6)
Midodrine (4) · Botulinum Toxins, Type A (2) · Buspirone (2) · Cholecalciferol (2) · Dextromethorphan (2) · Finasteride (2) · Lithium Carbonate (2) · NG-Nitroarginine Methyl Ester (2) · Resistance Training (2) · Riluzole (2) · Sodium Chloride (2) · Standard of Care (2) · Teriparatide (2) · Testosterone (2) · Transcranial Direct Current Stimulation (2)
US Department of Veterans Affairs (12) · VA Office of Research and Development (9) · James J. Peters Veterans Affairs Medical Center (7) · Kessler Foundation (5) · Chinese Academy of Sciences (3) · Hugo W. Moser Research Institute at Kennedy Krieger, Inc. (3) · Northwestern University (3) · Brigham and Women's Hospital (2) · China Spinal Cord Injury Network (2) · Icahn School of Medicine at Mount Sinai (2) · Shirley Ryan AbilityLab (2) · AOSpine North America Research Network (1) · Assistance Publique Hopitaux De Marseille (1) · Baylor College of Medicine (1) · BioArctic AB (1)
United States (68) · China (10) · Canada (9) · South Korea (4) · Switzerland (4) · Australia (3) · India (3) · Spain (3) · France (2) · Japan (2) · Chile (1) · Germany (1) · Hungary (1) · Israel (1) · Jordan (1)
Nancy Rocheleau, Program Analyst (5) · John Fryer, Ph.D. Asst. Director (4) · Ashraf Gorgey, PhD PT (3) · Thomas J Schnitzer, MD, PhD (3) · William Bauman, MD (3) · Christine N. Sang, MD, MPH (2) · Cristina L Sadowsky, MD (2) · Jianwu Dai, Ph.D (2) · Jill Wecht, EdD (2) · Joshua F Yarrow, PhD MS BS (2) · Thomas Bryce, MD (2) · Trevor A. Dyson-Hudson, M.D. (2) · Abdulghani Sankari, MD PhD (1) · Alexander Averyanov, MD (1) · Alok K Sharma, MS,MCh (1)
PMID 21762873, PMID 30334093, PMID 10569435, PMID 15663976, PMID 16398945, PMID 16793729, PMID 17046161, PMID 17385265, PMID 17475549, PMID 17965289, PMID 19648013, PMID 19651280, PMID 19799783, PMID 19903102, PMID 19996767, PMID 20801263, PMID 21252493, PMID 21303266, PMID 21372246, PMID 21381984, PMID 21717386, PMID 21949432, PMID 22105463, PMID 22232031, PMID 22525310, PMID 22985379, PMID 23295632, PMID 23343764, PMID 23700789, PMID 23844986, PMID 24401143, PMID 24968251, PMID 24987412, PMID 26394202, PMID 26705884, PMID 27901413, PMID 28864949, PMID 28948164, PMID 30794084, PMID 30845047, PMID 32352341, PMID 33264568, PMID 33443609, PMID 34278611, PMID 34713983, PMID 35366432, PMID 36662869, PMID 36875669, PMID 36899099, PMID 37045845
R01NS041503 (2), 1IK2CX000547 (1), 2014 (1), 2016 (1), 2025 (1), I01RX001449 (1), R01HD115345 (1), R01NS061304 (1), R03HD114768 (1), R21HD054697 (1), R21HD123083 (1), U01HD037439 (1)